Given the superior efficacy and high selectivity, pemafibrate is expected to overtake conventional PPARα agonists, in particular, fenofibrate, as the primary fibrate-based lipid-lowering drug in the treatment of dyslipidemia and CVD. The gene discussed is PPARA; the disease is metabolic syndrome.